Johnson & Johnson Innovation enter over 10 partnerships to further its health ambitions
Johnson & Johnson Innovation have announced 15 new partnerships which will support the development of new technologies and products across a number of fields and cater towards the growth of consumer healthcare.
“At Johnson & Johnson Innovation, we have a collaborative approach to partnering and tailor each deal to the needs of the company and its technology so we can accelerate the best science to solve today’s healthcare challenges,” commented Robert G. Urban, PhD., Global Head, Johnson & Johnson Innovation LLC.
“Our approach to external innovation has been incredibly fruitful, as we established more than 60 significant new strategic relationships in 2017.”
With ambitions to address ongoing healthcare challenges and improve the quality of life for patients on a global scale, the deals will explore the utilisation of artificial intelligence within fields such as Alzheimer’s disease, cancers and various disorders.
Johnson & Johnson Innovation aim to support the University of Pennsylvania within a new Gene Therapy Program to develop treatments to tackle the symptoms of Alzheimer’s disease.
Its collaboration with the Northern California Institute for Research and Education and the San Francisco Veterans Affairs Medical Center, the company will also be behind the study of the health of the brain, embedding new technologies to support ongoing developments.
Johnson & Johnson Innovation will further work to treat diseases of the central and enteric nervous systems, and has participated in the Series B financing of XW Laboratories Inc.
- The Australian Medical Association rekindles the debate for a sugar tax
- The US 2.3% medical devices tax is reinstated, impacting the medical manufacturing industry
- A new report by the Focus Clinic showcases the healthcare expenditure of countries worldwide
Investing in oncology is an area of which Johnson & Johnson Innovation are looking at with increased interest. Its collaboration with the Koch Institute for Integrative Cancer Research at MIT will see the companies conduct research aimed at eradicating lung cancer.
To support this, the company has also extended its collaboration with Queensland University of Technology (QUT), alongside Janssen Cilag Pty Ltd to create a saliva-based diagnostic for early detection of throat cancers.
Furthermore, both Johnson & Johnson Innovation and Janssen Pharmaceutica NV have formed a collaboration with MiRXES Pte Ltd to develop a novel lung cancer diagnostic test to improve the detection of early-stage disease.
Eye-related diseases and long-term conditions such as myopia are on the rise. Johnson & Johnson Innovation’s partnership with Queensland University of Technology will further the company’s research and development efforts to slow the progression of the condition through creating contact lenses able to support this goal.
Johnson & Johnson Vision, through its operating company Johnson & Johnson Vision Care Inc., has formed a collaboration with Narayana Nethralaya Foundation and Medical Research Foundation to develop diagnostic tools which can identify a person’s unique vision-care needs to provide personalised, tailored solutions to each patient options.
Finally, the company are working with the Taiwan Industrial Technology Research Institute to set up co-funding agreements for projects in lung cancer, chronic obstructive pulmonary disease, diabetes, eye health and digital health initiatives. This program will provide co-funding and mentoring to one or more research programs undertaken by public sector participants and start-up companies that meet the requisite factors and are jointly selected by the program founders.
Check Point: Securing the future of enterprise IT
Cybersecurity solutions provider Check Point was founded in 1993 with a mission to secure ‘everything,’ and that includes the cloud. Conscious that nothing remains static in the digital world, the company prides itself on an ability to integrate new technology with its solutions. Across almost three decades in operation, Check Point, with its team of over 3,500 experts, has become adept at protecting networks, endpoints, mobile, IoT, and cloud.
“The pandemic has been somewhat of an accelerator in the evolution of cyber risk,” explains Erez Yarkoni, Global VP for Cloud Business. “We had remote workers and cloud adoption a long time beforehand, but now the volume and surface area is far greater.” Formerly a CIO for several big-name telcos before joining Check Point in 2019, Yarkoni considers the cloud to be “part of [his] heritage” and one of modern IT’s most valuable tools.
Check Point has three important ‘product families’, Quantum, CloudGuard, and Harmony, with each one providing another layer of holistic IT protection:
- Quantum: secures enterprise networks from sophisticated cyber attacks
- CloudGuard: acts as a scalable and unified cloud-native security platform for the protection of any cloud
- Harmony: protects remote users and devices from cyber threats that might compromise organisational data
However, more than just providing security, Yarkoni emphasises the need for software to be proactive and minimise the possibility of threats in the first instance. This is something Check Point assuredly delivers, “the industry recognises that preventing, not just detecting, is crucial. Check Point has one platform that gives customers the end-to-end cover they need; they don't have to go anywhere else. That level of threat prevention capability is core to our DNA and across all three product lines.”
In many ways, Check Point’s solutions’ capabilities have actually converged to meet the exact working requirements of contemporary enterprise IT. As more companies embark on their own digital transformation journeys in the wake of COVID-19, the inevitability of unforeseen threats increases, which also makes forming security-based partnerships essential. Healthcare of Ontario Pension Plan (HOOPP) sought out Check Point for this very reason when it was in the process of selecting Microsoft Azure as its cloud provider. “Let's be clear: Azure is a secure cloud, but when you operate in a cloud you need several layers of security and governance to prevent mistakes from becoming risks,” Yarkoni clarifies.
The partnership is a distinctly three-way split, with each bringing its own core expertise and competencies. More than that, Check Point, HOOPP and Microsoft are all invested in deepening their understanding of each other at an engineering and developmental level. “Both of our organisations (Check Point and Microsoft) are customer-obsessed: we look at the problem from the eyes of the customer and ask, ‘Are we creating value?’” That kind of focus is proving to be invaluable in the digital era, when the challenges and threats of tomorrow remain unpredictable. In this climate, only the best protected will survive and Check Point is standing by, ready to help.
“HOOPP is an amazing organisation,” concludes Yarkoni. “For us to be successful with a customer and be selected as a partner is actually a badge of honor. It says, ‘We passed a very intense and in-depth inspection by very smart people,’ and for me that’s the best thing about working with organisations like HOOPP.”